tanimilast (CHF6001) / Chiesi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tanimilast (CHF6001) / Chiesi
NCT05373953: Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Completed
1
44
Europe
CHF6001
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
11/22
11/22
NCT06395610: Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Recruiting
1
24
Europe
CHF6001 DPI, Erythromycin
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
07/24
07/24

Download Options